Ranbaxy Laboratories (Delisted) share news and announcements
BSE: 500359
Last traded ₹859.80 on 1 Apr 2015
Delisted on 30 Mar 2016.
Ranbaxy Laboratories share news and announcements
790 announcements, routine notices left out, newest first. Page 2 of 16.
Nov 2014
27 Nov · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to news item dated November 27, 2014, captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard the Company has clarified that the news item has primarily quoted clarification issued by the Company on November 21, 2014 in response to the query from NSE. The parties to the suit have filed the Schedule for filing additional legal briefs before the US Court. There is nothing further to provide clarification in the matter.27 Nov · Legal
Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.26 Nov · Legal
Ranbaxy Laboratories Ltd had earlier informed to the Stock Exchanges that the Company has filed a complaint against the US FDA in D.C. Federal Court and had also asked the Court for a temporary ....26 Nov · Outcome of Allotment Committee Meeting
Allotment Committee of Directors at its meeting held on November 25, 2014, allotted 450,000 Equity Shares of Rs. 5 each for cash at par ....21 Nov · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy fails to block rivals in generic fight". The Company has clarified that " as the Company has earlier informed to the Stock Exchanges that the Company has filed a complaint against the US FDA in D.C. Federal Court and has also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided. The Court has not granted Temporary Restraining Order to block FDA approval for other ANDAs for generic version of Nexium and Valganciclovir However, the Court ordered the parties to the suit to agree up on a schedule for filing additional legal briefs addressing Ranbaxy s request for a preliminary injunction by Friday, November 21, 2014".21 Nov · Legal
Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy fails to block rivals in generic fight". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.19 Nov · Statement
6 Nov · Statement
5 Nov · Ranbaxy receives approval from US FDA to market Fenofibrate Capsules USP, 43 MG and 130 MG
Oct 2014
31 Oct · Updates
Company have received a letter on October 31, 2014 from the Luxembourg Stock Exchange (LSE) (where GDS of the Company are listed) intimating that in view of the termination of the Deposit Agreement on December 15, 2014, they will de-list the GDS from the official list of the LSE and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014.31 Oct · Delisting of GDS from Luxembourg Stock Exchange
With reference to the earlier letter dated October 16, 2014 regarding Termination of the Company's Global Depository Receipts Programme, In this regard, Ranbaxy Laboratories Ltd has now ....16 Oct · Legal
Exchange has sought clarification from the company with respect to news article appearing in Business Standard on October 15, 2014 titled "Sun, Ranbaxy may be asked to sell some business ....16 Oct · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Sun, Ranbaxy may be asked to sell some business for CCI approval to merger". The Company has clarified that "The news article suggests that the Competition Commission of India (CCI) may ask the parties to the merger to sell parts of their businesses as a pre-condition to approve the merger. Further, we wish to clarify that as on date we have not received any such communication from the CCI to divest any part of the business(s). The parties have made certain submissions to the CCI on which decision of the CCI is awaited. In view of the above, there is no requirement for disclosure under Clause 36 of the Listing Agreement as on date".16 Oct · Legal
Exchange has sought clarification from Ranbaxy Laboratories Ltd with respect to news article appearing in Business Standard on October 15, 2014 titled "Sun, Ranbaxy may be asked to ....16 Oct · Updates
Ranbaxy has settled the litigation concerning its participation in the Texas Medicaid Program. Under the settlement agreement, Ranbaxy will ....16 Oct · Termination of Global Depository Receipts (hereinafter "GDR") Programme
Company has notified the Bank of New York Mellon (hereinafter "The Bank") to terminate the Deposit Agreements dated July 7, 1994 (under ....13 Oct · Allotment of Equity Shares
ESOPs Allotment Committee of Directors at its meeting held on October 11, 2014, allotted 5,59,561 Equity Shares on exercise of stock options ....13 Oct · Disclosure
ESOPs Allotment Committee of Directors at its meeting held on October 11, 2014, alloted 5,59,561 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid- up Equity Share Capital of the Company post allotment is 424,572, 900 Equity Shares of Rs. 5 each aggregating Rs. 2,122,864,500/-.9 Oct · Shareholding Pattern For September 30, 2014
Sep 2014
29 Sep · Results
Meeting of the Board of Directors of the Company will be held on October 28, 2014, inter alia, to consider and approve Standalone and Consolidated ....24 Sep · Outcome of Court Convened Meeting of Equity Shareholders
17 Sep · Updates
Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which it reports pricing data for certain products eligible for reimbursement under the Medicaid program. The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation. The Company would fully cooperate with this civil investigation.17 Sep · Receipt of Civil Investigative Demand ("CID") from the United States Department of Justice
Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which ....
Aug 2014
25 Aug · Legal
Exchange had sought clarification with respect to the media report "Ranbaxy faces Rs.242 Crores fine in US for violations at Toansa" appearing in Business Standard on August 22, 2014. ....22 Aug · Court Convened Meeting of the Equity Shareholders of the Company on Sep 19, 2014
Jul 2014
30 Jul · Disclosure of Voting Pattern - Clause 35A